Heteroaryl derivatives as apelin receptor agonists

A compound represented by the Formula I:

• or a pharmaceutically acceptable salt thereof,
• wherein
• each of G1, G2, G3, and G4 is C, CH, or N, wherein:
• (a) G1 is CH, G2 is C, G3 is N, and G4 is N;
• (b) G1 is CH, G2 is N, G3 is C, and G4 is N;
• (c) G1 is N, G2 is N, G3 is C, and G4 is CH;
• or
• (d) G1 is N, G2 is N, G3 is C, and G4 is N;
• and
• the dashed ring A is heteroaromatic;
• R1 is
• wherein
• R11 is halogen, C1-6 alkoxy, or C1-6 haloalkyl;
• R12 is H, halogen, C1-6 alkoxy, or C1-6 haloalkyl;
• R2 is a 5- to 7-membered heteroaromatic ring with one or more heteroatom selected from O, N, or S, wherein R2 may be optionally substituted with one or more R21,
• wherein each R21 is halogen, C1-6 alkyl, C1-6 alkoxy, or C1-6 haloalkyl;
• R3 is
• wherein
• ring B is a 5- or 6-membered heterocyclic ring, optionally containing one or more degrees of unsaturation, and substituted with one or more R31,
• wherein each R31 is halogen, C1-6 alkyl, or oxo;
• each of R4 and R5 is H, CH3, or R4 and R5 combine with the atom to which they are attached to form a 3- to 6-membered cycloalkyl ring;
• and
• R6 is OH or NH—R61, wherein R61 is a 3- to 6-membered cycloalkyl ring.